Abril-Junio 2017 70
ISSN 1317-987X

Monografías docentes

Actualización en hepatitis C


1. Sabaki A. Hepatitis C virus entry: the early steps in the viral replicative cycle. Virol J 2009;4:117-125.

2. Organización Panamericana de la Salud OMS. Hepatitis vírica C. El Control de las Enfermedades Transmisibles. David L Heymann Editor. Décimoctava edición 2005. pág: 343-346. Washington.

3. Seeff L. Natural history of chronic hepatitis C. Hepatol 2002;36:S35-S46.

4. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834-3847.

5. Moradipour D, Penin F, Reel C. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-463.

6. Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 2009;117:49-65.

7. Simmonds P. Bukh J. Combat C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C. Virus genotypes. Hepatology 2005;42:962-973.

8. Delic D, Nesic Z, Prostran M, et al. Assessment of Chronic Hepatitis C Virus RNA and Genotypes from 110 Patients with Chronic Hepatitis C Infection in the Serbia. International Journal fo Infectious Diseases.2006. Lisbon. Portugal.

9. Marques N, Serra J, Saraira de Cunha J, Melico-Silvestre A. HCV Genotype 4: epidemiological and Clinical Report of 54 Patients. 12th ICID Abstracts. 2006:59012. Pág. S 269. Lisbon. Portugal.

10. Baseras M, Fernandez M, Sota M, et al. Changes in the Prevalence of Hepatitis C Virus Genotypes in Northen Spain During a Six-Year Period. International Congress of Infectious Diseases. 2006. Abstracts. Lisbon. Portugal.

11. Icardi G, Sticchi C, Riccio C. Different Seroprevalence and Molecular Epidemiology Patterns of Hepatitis C Virus Infection in Italy. 12th ICID. 2006. Abstracts: S275. Lisbon. Portugal.

12. Vigani A, Macedo de Oliveira A, Pavan M, et al. Comparative Study Between Hepatitis C Virus Genotypes 1 and 3 in Patients with Chronic Hepatitis. 12th ICID 2006. Abstracts: S 279. Lisbon. Portugal.

13. Liu Z, Robida J, Chinnaswamy S, et al. Mutations in the hepatitis C virus polymerase that increase RNA binding confer resistance to cyclosporine A. Hepatol. 2009;50:25-33.

14. Newmann A, Lana N, Dahori H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon.alpha therapy. Science. 1998;282:103-107.

15. Morikawa K, Zhao Z, Date T, et al. The roles of CD 81 and glicosaminoglycans in the adsorption and uptake of infections HCV particles. J Med Virol. 2007;79:714-723.

16. Molina S, Castet V, Fournier-Wirth C, et al. The low density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol. 2007;46:411-419.

17. Cormier E, Durso R, Tsamis F, et al. L SIGN (CD 209 L) and DC – SIGN (CD 209) mediate transinfection of liver cell hepatitis C virus. Proc Natl Acad Sci. USA. 2004;101:14067-14072.

18. Akazawa D, Date T, Morikawa K, et al. CD 81 expression is important for the permissiveness of Huh 7 cell clones for heterogeneous hepatitis C virus infections. J Virol. 2007; 81:5036-5045.

19. Grove J, Huby T, Stamakky Z, et al. Scavenger receptors BI BII expression levels modulate hepatitis C virus infectivity. J Virol. 2007;81:3162-3169.

20. Moe C, Grove J, Harris H, et al. Effect of cell polarization on hepatitis C virus entry. J Virol. 2008;82:461-470.

21. Blanchard E, Becouzard S, Gonestain L, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006;80:6964-6972.

22. Lavillette D, Bertoseh B, Noarrisson D, et al. Hepatitis C virus glycoproteins mediate low pH dependent membrane fusion with liposomes. J Biol Chem. 2006;281:3909-3017.

23. Bernfield M, Gotte M, Park P, et al. Functions of all surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777.

24. Barth H, Schnober E, Zhang F, et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol. 2006;80:10579-10590.

25. Lozach P, Lorat-Jacob H, de Lacroix A, et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem, 2003;278:20358-20360.

26. Pileri P, Vematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD8. Science. 1998;282:938-941.

27. Hemler M. Tetraspamin function and associated microdomains. Nat Rev Mol Cell Biol. 2005;6:801-811.

28. Cocgueril L, Kuo C, Dubusson J, Levy S. CD 81- dependent binding of hepatitis C virus E1 E2 heterodimers. J Virol. 2003;77:10677-10683.

29. Bertaux C, Dragic T. Different domains of CD 81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J Virol. 2006;80:4940-4948.

30. Flint M, Maidens C, Loomis-Price L, et al. Characterizations of hepatitis C virus E glycoprotein interaction with a putative cellular receptor CD 81. J Virol. 1999;73:6235-6244.

31. Cornier E, Tsamis F, Kajumo F, et al. CD 81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA. 2004;101:7270-7274.

32. Rigotti A, Acton S, Kriegar M. The class B scavenger receptors SR-B1 and CD 36 are receptors for anionil phospholipids. J Biol Chem. 1995;270:16221-16224.

33. Heo T, Lee S, Barteach B, et al. Hepatitis C virus E2 links soluble human CD 81 and SR –B 1 protein. Virus Res.. 2006;121:58-64.

34. Evans M, von Hann T, Tacherne D, et al. Claudin -1 is a hepatitis C virus co-receptor required for a later step in entry. Nature. 2007;446:801-805.

35. Ploss A, Evans M, Gaysinskaya V, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 2009;47:882-886.

36. Reynolds G, Harris H, Jennings A, et al. Hepatitis C virus receptor expression in normal and disease liver tissue. Hepatol. 2008;47:418-427.

37. Lehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of co-evolution and coexistence. J Clin Invest. 2009; 119:1745-1754.

38. Rubin E, Farber J. El hígado y las vías biliares. La patología de las hepatitis aguda y crónica. En: Patología Rubin/Farber. Editorial Médica Panamericana. Buenos Aires.1998. Pág. 675-679.

39. Rubin E, Farber J. Cirrosis. En: Patología Rubin/Farber. Editorial Médica Panamericana. Buenos Aires.1998. Pág. 691-693.

40. Organización Panamericana de la Salud. Hepatitis vírica C. En: El control de las enfermedades transmisibles. David L. Heymann Editor. Decimonovena edición, 2011. Pág: 397-400. Washington.

41. Seef L. Natural history of chronic hepatitis C. Hepatol 2006; 36:535-546.

42. Levrero M. Viral hepatitis and liver cancer: The case of hepatitis C. Oncogene 2006; 215:3834-3847.

43. Rubin E, Farber J. Neoplasias Malignas. Carcinoma hepatocelular. En: Patología Rubin/Farber. Editorial Médica Panamericana. Buenos Aires.1998. Págs. 719-721.

44. Isada C, Kasten B, Goldman M, et al. Hepatitis C Virus. In: Infectious Diseases. Layi-Comp. Chicago.1999. Pág. 103-105.

45. Kao H, Ran F, Guan W, et al. Evaluation of the permanence of the E1 Agen HCV test for detection of hepatitis C virus infection. J Viral Methods. 2009; (E pub ahead of print).

46. McGovern B, Birch B, Bowen M, et al. Improving the diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria. Clin Infect Dis. 2009; 49:1051-1060.

47. Reyes H, Navarro P, Hepatitis viral. En: Enfermedades Infecciosas Virales. Editorial Disinlimed.1998. Pag: 327-365.Caracas.

48. Resouli M, Ziagen M, Abbasian A, et al. HCV/HIV Co-Infection in Iranian patients. 12th ICID 2006. Abstracts. 5900. Pag. 3268. Lisbon. Portugal.

49. Marques N, Serra J, Saraira de Cunha J, Melico-Silvestre A. Epidemiological, Clinical and Histological Aspects in Mono-infected and Co-infected (HIV) Patients. 12th ICID 2006.Abstracts: 59011. Pag. S269. Lisbon. Portugal.

50. Crockett S, Keeffe E. Natural history and treatment of hepatitis B virus and hepatitis C virus co-infection. Ann Clin Microbiol Antimicrob 2005;4:13-18.

51. Lee W. Hepatitis virus infection. N Engl J Med. 1997;227:1733-1745.

52. Centers for Diseases Control and Prevention. Recommendation for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47:1-39.

53. Dovi K, Singh N, Mara J, et al. Seroprevalence of Hepatitis B vírus and Hepatitis C vírus among Hepatic Disorders and Injecting Drugs Users in Manipur. A Preliminary Report. Indian J Med Microbiol. 2004;22:136-137.

54. Pallas J, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Co-infections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur Epidemiol.1999;15:699-704.

55. Reddy G, Dakshinamurthy K, Necladresad P, et al. Prevalence of HBV and HCV dual infection in patients on hemodialysis. Indian J Med Microbiol. 2005;23:41-43.

56. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136

57. Kabinowska-Nowak A, Bociaga-Lasik M, Garlicki A, Skaware P. Prevalence of hepatotropic viruses HBV and HCV in HIV infected patients from Southern region of Poland. Acta Virol. 2000; 44: 23-28

58. Irshad M, Peter S. Spectrum of viral hepatitis in thalassemic children receiving multiple blood transfusions. Indian J Gastroenterol. 2002;21:183-184.

59. Saravanam S, Vijayakumar V, Nandakumar S, et al. Hepatitis B vírus and hepatitis C vírus dual infection, among patients with chronic liver disease. J Microbiol Immnunol Infect. 2009;4:122-128.

60. Liaw Y. Concurrent hepatitis B and C virus: is hepatitis C virus stronger? J Gastroenterol Hepatol. 2001;16:597-598.

61. Jardi R, Rodríguez F, Buti M, et al. Role hepatitis B, C and D viruses in dual and triple infection influence of viral genotypes and hepatitis B precore and viral core promoter mutations in viral replicative interference. Hepatol. 2001;34:404-410.

62. Crespo J, Lozano J, de la Cruz F, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 2004;8:1147-1151.

63. Zarski J, Bohn B, Bastic A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. Hepatol. 1998;28:27-33.

64. Kim YK, Kim Y, Shimm S. Thoracic complications of liver cirrhosis; radiologic findings. Radiograph. 2009;29:825-837.

65. Tosti M, Mariano A, Blanco E, et al. Extra-hepatic Cancer Incidence Among Patients with Hepatitis C Virus Infections. A cohort Study. Int J Infect Dis. 2006.Abstracts. 5901. Pág:3268. Lisbon. Portugal.

66. Organización Panamericana de la Salud. OPS. Tratamiento de las Enfermedades Virales. En: Tratamiento de las Enfermedades Infecciosas. 3ª Ed. 2008. Pág. 200-217. Washington.

67. Pisula A, Janczewska-Kazek E, Smalyk A, et al. Re- therapy with Pegylated interferon and Ribavirin in Patients with Chronic Hepatitis Previously Treated with Interferon Alfa and Ribavirin. 12th ICID. 2006. Abstracts. Vol 10. S 272. Lisbon. Portugal.

Actualización en hepatitis C
Anatomía Patológica
Manifestaciones clínicas

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.

Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
Este portal ha sido desarrollado gracias al apoyo del Fonacit